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Wieser and colleagues, in a study published in Swiss Med-
ical Weekly in July 2018, compared incidence rates of
ovarian cancer derived from the cantonal cancer registries
(CCRs) as published by the National Institute for Cancer
Epidemiology and Registration (NICER) with those de-
rived from the hospital discharge data compiled by the
Swiss Federal Statistical Office. The authors observed a
substantial difference between these two estimates. The av-
erage age-adjusted ovarian cancer incidence rate was 14.6
per 100,000 women per year over the period 2004–2012
compared with a rate of 11.3 per 100,000 women per year
reported by NICER for the same period [1]. The authors
argue that the figure provided by NICER is probably an
underestimation of the true figure because cancer registry
data are based on voluntary information on new cases from
clinicians. With our response, we show that this conclusion
is not correct and the observed high rate of ovarian cancer
in hospital discharge data is an artefact, probably arising
from incorrect coding of non-malignant ovarian tumours.
Further, we explain the purpose of epidemiological cancer
registries and their difference from routinely collected dis-
charge data.
Population-based (or epidemiological) cancer registries
collect data from multiple sources on all new cancer cases
occurring in a well-defined population, resident in a partic-
ular geographical region (e.g., canton). Their main objec-
tive is to produce statistics on the occurrence of cancer in a
defined population and to provide a framework for assess-
ing and controlling the impact of cancer in the community
[2]. The key data sources are pathology laboratories, hos-
pital records and death certificates, but also records from
other facilities such as radiotherapy and oncology depart-
ments, imaging facilities and haematology laboratories, as
well as hospital discharge data [3].
Epidemiological cancer registries were developed in
Switzerland on a cantonal level starting the early 1970s,
when the registries in Geneva, Vaud and Neuchatel were
established [4]. In the 1980s, the registries in Zurich, St
Gallen and Basel followed. By now, all but two cantons
register cancer cases and, according the Federal Law on
Cancer Registration (Bundesgesetz über die Registrierung
von Krebserkrankungen (KRG); SR 9918.33), they also
will start registration in 2020. In 2007, NICER was found-
ed as a collaborative network to promote and support na-
tional population-based cancer registration and epidemi-
ological cancer research in Switzerland. Since then,
cantonal data have been combined to generate updated na-
tional cancer incidence and mortality statistics for public
use [5].
Hospital discharge data are primarily collected and defined
for administrative and reimbursement purposes [6].
Switzerland introduced the Swiss Diagnosis Related
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Groups (SwissDRG) on 1 January 2012 with the aim to
promote cost containment, efficacy and transparency in
hospital financing. Before that date, various reimburse-
ment systems were applied depending on the canton [7].
Wieser et al. [1] argue that the incidence of ovarian cancer
reported by NICER and the Swiss cantonal cancer reg-
istries is underestimated because registry data are based on
voluntary information on new cases from clinicians. Based
on our experience in cancer registration, we strongly be-
lieve that under-registration of cases is not the explanation
for the observation made by Wieser et al. [1]. Complete-
ness of case ascertainment is regularly checked regional-
ly (by Swiss cancer registries), nationally (by NICER) and
internationally (by the International Agency for Research
in Cancer). In general, data quality indicators published
by NICER and Cancer Incidence in Five Continents (CI5)
suggest completeness above international standard.
However, in order to evaluate further a potential systematic
underestimation of cancer cases by the cantonal cancer
registries, we compared incidence rates based on NICER
data and on the hospital discharge data between 2011 and
2014. We selected two rare cancers with a high fatality rate
very likely to be hospitalised (liver cancer [C22], pancre-
atic cancer [C25]) and three common cancers all likely to
be hospitalised (intestinal cancer [C17-C21], breast cancer
[C50] and lung cancer [C33/34]). Table 1 shows the age-
standardised rates per 100,000.
For pancreatic cancer (men and women), lung cancer (men
and women), intestinal cancer (men and women), and liver
cancer (men), the age-specific rates for 2011–14 based on
NICER data were 7.6% to 22% higher than rates based on
hospital discharge data. Compared with NICER, incidence
rates of breast cancer and liver cancer in women were high-
er based on hospital discharge data, although the relative
difference is much smaller compared with ovarian cancer.
We evaluated in several registries how many cases re-
ceived from the hospital discharge data turned out, after
excluding prevalent and nonresident cases, not to be ma-
lignant ovarian cancer cases. After careful review of the
pathology reports, 21–62% of all ovarian cancer cases re-
ported by the hospital discharge data turned out to have a
diagnosis of D39 (neoplasm of uncertain or unknown be-
haviour of female genital organs) or a completely differ-
ent diagnosis. Although this is only evidence from some of
the Swiss registries, the additional cases show a substantial
proportion of misreporting on hospital discharge records.
A study from Northern Ireland also reported a rather high
proportion of wrongly coded ovarian cancer cases, leading
to an overestimation of the incidence of ovarian cancer by
hospital discharge data, though to a lower extent than in
our comparison [8].
Our comparison of the two data sources does not show
a general pattern of higher rates based on hospital dis-
charge records. This argues against a systematic underre-
porting of cancer cases by data providers to the CCRs. Al-
though it is true that in many cantons reporting of cases
to the CCRs is or was not mandatory (e.g., in the canton
of Zurich until 2016), almost all pathology institutes, hos-
pitals and physicians participated in cancer registration.
More importantly, underreporting, if based on non-report-
ing by certain hospitals, pathologists or physicians should
not result in selective underreporting of one cancer site or
in only one sex. In a previous evaluation of the complete-
ness of case ascertainment in Swiss cancer registries [9],
potential underregistration of ovarian cancer cases in the
CCRs Basel and Zurich was observed. There is, howev-
er, no indication of substantial underregistration of ovarian
cancer cases in Switzerland overall [9]. Notably, a recalcu-
lation of the average age-adjusted ovarian cancer incidence
rate (2004–2012) excluding data from the CCRs Basel and
Zurich remained comparable (11.9 per 100,000 women per
year).
Importantly, hospital discharge data do not include infor-
mation about the disease status of the patient (incident vs
prevalent case). Wieser et al [1] addressed this issue by
counting patients with a first ovarian cancer diagnosis as
the main reason for hospital stay after an event-free period
of six years and additional diagnoses in precedent hospital-
isations of this individual. This approach might have two
limitations. Firstly, it assumes high data quality before and
after the introduction of SwissDRG (the analysis is mainly
based on pre-SwissDRG data). To the best of our knowl-
edge, no data quality report on Swiss hospital discharge da-
ta is publicly available. However, experiences from other
countries give rise to doubts concerning the pre-SwissDRG
period [10]. Secondly, malignant neoplasms may be detect-
ed during a hospital stay due to another health problem
(and therefore mentioned only as additional diagnoses),
and the first hospitalisation with this cancer as main diag-
nosis, hence, may occur only few weeks or months later.
In conclusion, we can rule out a systematic underregistra-
tion of ovarian cancer in the CCRs. Furthermore, there is
support for the notion of misclassification of ovarian can-
cer in Swiss hospitals.
For a valid judgement, a thorough case-to-case alignment
of hospital in-patients with an ovarian cancer diagnosis and
their capture during cancer registration would be needed.
However, with its systematic data collection using multi-
ple sources and established regular quality control accord-
ing to internationally valid standards, cancer registration as
performed by the CCRs in Switzerland still provides the
most reliable cancer incidence data in Switzerland.
Table 1: Age-standardised incidence rates* of selected cancer sites for the period 2011–2014 according to hospital discharge data and NICER data, with their relative difference.
Hospital discharge data (“Wieser” method) NICER Relative difference
Male Female Male Female Male Female
Ovary 14.2 10.6 −34.0%
Breast 119.2 111.7 −6.7%
Pancreas 11.0 8.9 12.4 9.8 +11.3% +9.2%
Lung 38.7 24.0 49.6 28.4 +22.0% +15.5%
Intestine 45.6 31.5 49.8 34.1 +8.4% +7.6%
Liver 10.3 3.8 11.6 3.4 +11.2% −11.8%
NICER = Swiss National Institute for Cancer Epidemiology and Registration * Average rates computed from the rates per year using the European Standard population (1976)
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